Bars

S2-E24.3 – From The Fourth Global NASH Congress — How Diagnostics Will Evolve Over The Next Several Years

After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around competing strategies for diagnostic testing as the NASH market evolves.

After hearing presentations from 43 speakers at the Fourth Global NASH Congress, the Surfing the NASH Tsunami team convenes one more time to debate how the diagnostics market will develop. With a profusion of options, physicians, payers and regulators will have decisions ahead. There is some disagreement on the year in which events will happen, but not on the basic pattern of market evolution.

TOPICS: cirrhosis, COVID-19, ELF, FIB-4, FibroScan, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, NAFLD, NASH, Siemens Healthineers, NIS-4, NASHnext, LabCorp,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

The NASH Tsunami In Diabetes

Categories for NASH Tsunami
Allied Health Professionals Cirrhosis Clinical Trials Companies COVID-19 Diabetes Diagnostics Digital Health Digital Therapeutics Doctors Drugs/Drug Classes Drug therapies Endocrinology clinics Epidemiology Fatty Liver FDA FIB-4 GLP-1s Guidelines Hepatology Histopathology Inside The Vault Investors Liver Science Major Meetings Metabolic Diseases Motivating front-line treaters NAFLD NAFLD Prevalence NAIL-NIT NASH NASH-TAG NASH/Diabetes Co-Morbidity NITs Obesity Patient Advocacy Patients Pediatric NASH Podcast Prevalence/Incidence Public Health Rising Tide Special Subpopulations Suggested Reading Type 2 Diabetes Mellitus

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Apple Spotify Youtube Soundcloud
More Episodes
Log In
Stay In Touch
Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME